Single-tracer Multiparametric PET Imaging
NCT06014515 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2026-03-10
Summary
The overarching goal of this project is to develop and evaluate a single-tracer multiparametric positron emission tomography (PET) imaging solution for simultaneous imaging of blood flow and glucose metabolism using 18F-fluorodeoxyglucose (FDG) alone. The investigators working hypothesis is that quantitative blood flow can be extracted from dynamic 18F-FDG PET data by use of tracer kinetic modeling, in addition to glucose metabolism that 18F-FDG is conventionally used for.
Conditions
- Healthy Subjects
- Cardiovascular Disease
Interventions
- DRUG
-
18F-FDG
Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
- DRUG
-
11C-butanol
Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
Sponsors & Collaborators
-
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
collaborator NIH -
University of California, Davis
lead OTHER
Principal Investigators
-
Guobao Wang, PhD · University of California, Davis
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-02-14
- Primary Completion
- 2028-08-31
- Completion
- 2033-08-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
NCT01806675 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke
NCT04571177 ·Status: ACTIVE_NOT_RECRUITING
-
Multi-Tracer Pet Quantitation of Insulin Action
NCT00715221 ·Status: COMPLETED
-
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
NCT01931709 ·Status: TERMINATED ·Phase: NA
-
Dual-Tracer Theranostic PET
NCT05680675 ·Status: COMPLETED ·Phase: NA
-
Impact of 100mL Lipid Emulsion for Intravenous for Suppression of Myocardial Glucose Metabolism in 18F-FDG PET/CT
NCT04437927 ·Status: COMPLETED
-
PET Imaging of Regional Variation in Insulin Sensitivity of Adipose Tissue in Humans
NCT00222768 ·Status: COMPLETED
-
PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)
NCT00201942 ·Status: COMPLETED ·Phase: PHASE3
-
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
NCT00207298 ·Status: COMPLETED
-
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
NCT03846167 ·Status: ACTIVE_NOT_RECRUITING
-
Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus
NCT00222781 ·Status: COMPLETED
-
Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated Venothromboembolism
NCT01107327 ·Status: COMPLETED
-
Multi-Tracer PET Quantitation of Insulin Action in Muscle (Phase 1, Phase 2, Phase 3, Phase 4)
NCT00222885 ·Status: COMPLETED
-
Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation
NCT01100671 ·Status: COMPLETED
-
PET Imaging of PARP Activity in Cancer
NCT02469129 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology
NCT01180751 ·Status: UNKNOWN ·Phase: PHASE3
-
18F-FMAU PET/CT in Imaging Patients With Advanced Cancers
NCT02079181 ·Status: TERMINATED ·Phase: NA
-
Correlation Between Various Adipokines and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) (18FDG-PET)
NCT01150006 ·Status: COMPLETED
-
Ultralow Dose PET Imaging of 18F-flurpiridaz
NCT07284576 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Renal Blood Flow Measurement With Positron Emission Tomography (PET)
NCT00714142 ·Status: COMPLETED ·Phase: PHASE2
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT03604315 ·Status: RECRUITING ·Phase: PHASE1
-
Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer
NCT05625217 ·Status: COMPLETED ·Phase: NA
-
Study of 18F-Fluoro-PEG6-IPQA
NCT01320059 ·Status: COMPLETED ·Phase: PHASE1
-
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
NCT01383135 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
NCT02378337 ·Status: COMPLETED